Skip to main content

Avascular Necrosis Market Size, Growth Factors and Trend Forecast To 2024

 Market Highlights

Avascular necrosis (AVN) is a common cause of musculoskeletal disability and has placed itself as a foremost challenge both therapeutically and diagnostically in recent years. The incidence of avascular necrosis globally has seen a significant rise in recent times. Trauma is identified as the most common reason of avascular necrosis; however, nontraumatic AVN is found to be occurring usually in younger adults.

The avascular necrosis market is projected to increase at a CAGR of 6.58 percent during the forecast period (2018-2024) and is projected to reach valuation of USD 1.12 Bn by 2024. The avascular necrosis market globally is motivated by the growing occurrence of bone diseases such as osteoarthritis and osteoporosis together with the mounting cases of alcohol abuse and steroids, and implementation of the medication over surgery by the patients. However, strict regulatory requirements and lack of awareness in a majority of the population may curb the progress of the market in the forecast period.

Competitive Analysis

The competitors in the market are also leveraging their competitive benefits to protect their growth in the market. The companies in the market are persistently trying to establish leading market positions through new policies and strategies. The key trends and players have established a positive tone for development. The experienced management in the companies functioning in the market is creating business models which can bring about a productive phase of development. The competitors in the market are trying to succeed commercially by ensuring demand and supply are in balance.

Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/6131

On the other hand, the rising levels of awareness of the medical condition of avascular necrosis among physicians and patients in these countries is an evident growth promoter of the market. The persons between the ages of 30 to 50 years are usually found to be affected, and males are more generally affected than females. Additionally, the expansions in therapeutic technologies such as gene therapy and stem cell-based osteonecrosis treatment are also anticipated to boost the market’s progress. The primary treatment regimen primarily comprises medications such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) for reducing pain and swelling, cholesterol-lowering drugs, and blood thinners. These drugs might control the symptoms of the disease but are not yet capable of providing far-reaching cure to the condition. Thus, in these cases, surgery becomes the vital treatment for curing avascular necrosis. Though, the original Advanced Therapy Medicinal Products (ATMPs) are projected to boost the market.

Segmental Analysis

The segments on the basis of type, site, diagnosis, treatment, end-user, and region are used for the segmentation of the avascular necrosis market globally. By type, the market has been segmented non-trauma related avascular necrosis (AVN) and into trauma-related avascular necrosis (AVN). The non-trauma related avascular necrosis segment presently is credited for the major market share and is expected to continue to be extremely productive throughout the assessment period. By site, the segmentation of the market includes knee, hip bone, shoulder, and other. In the year 2017, the hip bone segment was worth USD 508 Mn approximately. By diagnosis, the market has been segmented into biopsy and imaging. The imaging segment at present is attributable for the biggest market share in the year 2017. The treatment segment of the market has comprises of electrical stimulation, medication, gene therapy, and surgery. Among these segments, the oncology segment is anticipated to develop with the peaking CAGR percent during the forecast period. The end user segment the market has been segmented into diagnostic centers, hospitals & clinics, and ambulatory surgical centers. The hospitals & clinics will probably retain its top position by the end of 2024.

Regional Analysis

The region wise segmentation of the market comprises of regions such as Europe, Americas, the Middle East & Africa (MEA) and Asia Pacific (APAC). The Americas region is presently attributed for the chief market share, and the trend is expected to carry on in the foreseeable future. This is attributable to the robust value upheld by the hip bone replacement segment in both the U.S. and other Latin American nations. Furthermore, the medical device industry is one of the principal ventures in the US. The Asia Pacific and European regions are also anticipated to continue its significant growth in various revenue pockets for the avascular necrosis (AVN) market during the forecast period. While the APAC region’s trajectory is mostly directed by factors such as improved equipment and infrastructure and intensifying R&D initiatives to increase the effectiveness and efficacy of new drugs. The increasing demand for reduced cost of treatment procedures in emerging countries such as China and India has improved the demand development of minimally invasive surgeries. These two nations are responsible for almost 40% of the total global population affected with AVN disease. Strict regulatory requirements and absence of awareness in the majority of the population may confine the expansion of the market in the asessment period.

Access Report Details @  https://www.marketresearchfuture.com/reports/avascular-necrosis-market-6131

Ethicon Inc., Sanofi SA, Wright Medical Group N.V., Bayer AG, Pfizer Inc., Merck KGaA, Aurobindo Pharma, Eli Lilly and Company, Zimmer Biomet Holdings, Stryker Corporation, Medtronic plc, Boehringer Ingelheim GmbH, Integra LifeSciences Corporation, Smith and Nephew, Grifols SA, and others.

TOC:

  1.  Report Prologue    

    2.    Market Introduction   


          2.1    Definition    

          2.2    Scope of the Study    

                2.2.1    Research Objective    

                2.2.2    Assumptions    

                2.2.3    Limitations    

    3.    Research Methodology

          3.1    Introduction

          3.2    Primary Research    

          3.3    Secondary research

          3.4    Market Size Estimation

    TOC…Continued

Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/6131

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Comments

Popular posts from this blog

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Growth Drivers, Restraints and Opportunities, Forecast To 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 Global  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size  Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. Some of the key players operating for the global market analysis are  Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La R...

Peptic Ulcer Drugs Market Rapid Development By Manufactures Business Growth Future

  Peptic Ulcer Drugs Market Scenario: Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors. Peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach. Peptic ulcer includes gastric, esophageal and duodenal ulcer. The global peptic ulcer drugs market was valued at approximately $29 billion in 2015, and is expected to reach $36.27 billion by 2022. Thus, the market is expected to show an average growth at a CAGR of 3.8 % from 2016 to 2022. The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use. Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics. Avail a Free Sample@  https://www.market...

Middle East And Africa Pediatric Healthcare Market Development Research with Forthcoming Opportunities and Challenges

  Middle East And Africa Pediatric Healthcare Market Share, Application And Growth Analysis, By Type Of Diseases (Short Term Diseases, Chronic Diseases And Others), By Therapeutics (Cardiology, Allergy And Immunology, Gastroenterology, Infectious Disease And Others), By Treatment (Medication, Surgery, And Others) - Forecast To 2023 Paediatric Healthcare-Overview Paediatrics is a branch of medicine which deals with diagnosis and treatment of diseases related to paediatric group. It can be classified into the four categories namely neonates (from birth till the first 28 days of life), infants (29 days to 2 years), children (2 years to 12 years) and adolescents (12 years to 18 years). Paediatrician is a medical professional who specializes in providing treating the paediatric group. Paediatric medical devices are devices used for the treatment and care of infants and children below 18 years having some healthcare issues. Avail a Free Sample@  https://www.marketresearchfuture.com/...